RE:RE:possible good news...I simply said possible for 2 reasons: 1. The link between GSK and PLI is not official....(but I'm confortable...) 2. GSK must now allow sufficient ressources for the marketing and selling of the product. So, it's good news in my head, but official confirmation to the market will be required to impact somehow the stock. What PLI was controlling is the quality of the ligand to purify GSK albumine, and they succeeded. Now the rest of the story belong to GSK. Just to say how long things can take to bring to commercial stage some contract, this one goes back to 2004. But, it also give a confirmation of the superiority of PLI technology, knowing that GSK rather like to sign with a small unknow company (in 2004) instead of a key player of the industry of plasma fractionnation. Here the original NR for the nostalgic.... ProMetic Announces Contract with GlaxoSmithKline Purification materials and processes to be developed based on ProMetic’s Mimetic Ligand™ technology MONTREAL, Canada, July 6, 2004 – ProMetic Life Sciences Inc. (TSX: PLI) announced today that its wholly owned subsidiary ProMetic BioSciences Ltd. has signed a contract with GlaxoSmithKline (GSK) to provide GSK access to ProMetic’s unique affinity purification technology. Financial terms were not disclosed. Under the agreement, ProMetic will develop affinity materials and purification process steps for the isolation and purification of therapeutic proteins of interest to GSK. This will provide GSK with state-of-the-art purification materials and technology which enable accelerated product and process development, high product yields, optimal process economics, and regulatory compliance. Mimetic Ligands™ will be developed for the purification of target proteins using ProMetic’s Intelligent Combinatorial Libraries® discovery platform. Selected ligands will be attached to Prometic’s support materials and manufactured to the high quality standards required for the production of biotherapeutic products.